MedImmune Message Board - Msg: 19459565

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (255)	11/3/2003 9:36:43 AM
From: tuck	Read Replies (1) of 416

From Briefing.com: >>8:50AM Wyeth: FluMist running below initial estimates (WYE) 44.14: Thomas Weisel says that field checks of pharmacies and physicians' offices suggest demand for FluMist is running below initial estimates, as the $60-$80 payment is causing most patients to stay with the $15 traditional flu injection; firm says another indication of the weak demand is that WYE recently initiated a $25 rebate coupon program for FluMist at select locations, yet firm thinks that this is unlikely to spur significant demand; firm cuts their FluMist sales est for 2003 to $75 mln from $125 mln and their 2004 est to $225 mln from $440 mln, and cuts their 2004 EPS est below consensus. (Note that WYE is a partner with MEDI for the FluMist drug.)<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next